- Home
- WLAC vs TLSI Comparison
WLAC vs TLSI Comparison
Compare WLAC & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLAC
- TLSI
- Stock Information
- Founded
- WLAC 2024
- TLSI 2010
- Country
- WLAC United States
- TLSI United States
- Employees
- WLAC N/A
- TLSI N/A
- Industry
- WLAC
- TLSI Medical Specialities
- Sector
- WLAC
- TLSI Health Care
- Exchange
- WLAC Nasdaq
- TLSI Nasdaq
- Market Cap
- WLAC 171.5M
- TLSI 158.0M
- IPO Year
- WLAC 2024
- TLSI N/A
- Fundamental
- Price
- WLAC $9.96
- TLSI $5.77
- Analyst Decision
- WLAC
- TLSI Strong Buy
- Analyst Count
- WLAC 0
- TLSI 6
- Target Price
- WLAC N/A
- TLSI $11.75
- AVG Volume (30 Days)
- WLAC 9.5K
- TLSI 40.4K
- Earning Date
- WLAC 01-01-0001
- TLSI 03-27-2025
- Dividend Yield
- WLAC N/A
- TLSI N/A
- EPS Growth
- WLAC N/A
- TLSI N/A
- EPS
- WLAC N/A
- TLSI N/A
- Revenue
- WLAC N/A
- TLSI $26,891,000.00
- Revenue This Year
- WLAC N/A
- TLSI $61.29
- Revenue Next Year
- WLAC N/A
- TLSI $53.21
- P/E Ratio
- WLAC N/A
- TLSI N/A
- Revenue Growth
- WLAC N/A
- TLSI 67.90
- 52 Week Low
- WLAC $9.95
- TLSI $3.50
- 52 Week High
- WLAC $10.50
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- WLAC N/A
- TLSI 68.94
- Support Level
- WLAC N/A
- TLSI $5.40
- Resistance Level
- WLAC N/A
- TLSI $5.82
- Average True Range (ATR)
- WLAC 0.00
- TLSI 0.24
- MACD
- WLAC 0.00
- TLSI 0.01
- Stochastic Oscillator
- WLAC 0.00
- TLSI 89.19
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.